Q4 2025 Maravai LifeSciences Holdings Inc Earnings Call Transcript
Key Points
- Maravai LifeSciences Holdings Inc (MRVI) reported full-year revenue of $185.7 million, exceeding guidance by $700,000.
- The company achieved positive adjusted EBITDA of over $500,000 in Q4, marking a significant improvement from previous quarters.
- Strong performance was driven by GMP consumables and CDMO services at TriLink, and increased demand for protein kits at Cygnus.
- The company exceeded its cost-saving targets, achieving over $50 million in savings as part of its restructuring efforts.
- Maravai LifeSciences Holdings Inc (MRVI) has increased direct customer engagement, leading to strong demand for its GMP enzymes and other products.
- Q4 revenue was $49.9 million, down from $56.6 million in Q4 2024, primarily due to a decrease in high-volume COVID-related sales.
- The company reported a GAAP net loss of $63 million for Q4, including significant non-cash impairment and restructuring charges.
- Revenue from the TriLink segment decreased by 17% year-over-year, excluding COVID-related sales.
- The company faces challenges with lumpiness in order volumes, which can impact revenue predictability.
- Despite improvements, the company still reported a basic and diluted loss per share of $0.24 for Q4.
Hello and welcome everyone joining today's Maravai Life Sciences Q4 2025 results earnings call.
At this time, all participants are in a listen-only mode.
Later, we will, you will have the opportunity to ask questions during the question-and-answer session.
To register to ask a question at any time, please press star one on your telephone keypad.
Please note this call is being recorded.
We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Deb Hart.
Please go ahead.
Good afternoon, everyone. Thanks for joining us on our fourth quarter and year in 2025 earnings call. The press release and slides accompanying today's call are posted on our website and available at investors.moravai.com.
As you can see from the agenda on slide 2, our CEO Bern Brust will provide a business update and our CFO Raj Asapoda will review our financial results. Doctor Chamfeng Zhao, our Chief Scientific Officer, will join us for our Q&A
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
